⚠️ RESEARCH PURPOSES ONLY — This compound is not FDA authorized for human consumption. All referenced data is presented for informational and educational purposes only.
SS-31 10MG
$30.00
Availability: 10 in stock
How It Works
Mitochondria-targeted cardiolipin interaction studied in 100+ preclinical and clinical publications
Inner Mitochondrial Membrane Stabilization
SS-31 selectively concentrates in the inner mitochondrial membrane (IMM) where it binds to cardiolipin — a unique phospholipid exclusive to mitochondria. This interaction stabilizes cardiolipin's structure, which is critical for cristae morphology and the assembly of electron transport chain (ETC) supercomplexes.
- Binds cardiolipin at the inner mitochondrial membrane
- Stabilizes ETC supercomplex assembly
- Restores cristae morphology in damaged mitochondria
Mitochondrial Reactive Oxygen Species Reduction
The dimethyltyrosine (Dmt) residue within SS-31's sequence confers potent antioxidant capacity concentrated at the site of ROS generation. In preclinical models of ischemia-reperfusion injury, SS-31 administration was associated with significantly reduced mitochondrial superoxide production and preserved electron transport chain efficiency.
- Dmt residue provides targeted antioxidant capacity
- Reduces mitochondrial superoxide generation
- Preserves electron transport chain efficiency
Bioenergetic Function Restoration
By preserving cardiolipin integrity and reducing oxidative damage to ETC complexes, SS-31 supports restoration of the proton gradient across the IMM and improved ATP synthase function. Preclinical data in aged rodent models demonstrated improved mitochondrial membrane potential and ATP production rates.
- Restores mitochondrial membrane potential
- Improves ATP synthase coupling efficiency
- Enhances mitochondrial respiration in aged tissue models
What Research Has Shown
Key preclinical and early clinical findings from published studies
Research Applications
Primary areas of investigation
Heart Failure
Phase II PROGRESS-HF trial investigated Elamipretide in heart failure with reduced ejection fraction (HFrEF). Data demonstrated improvements in cardiac output, 6-minute walk distance, and quality of life scores.
Daubert MA et al. 2017 ↗Reperfusion Injury
In rodent models of myocardial and renal ischemia-reperfusion injury, SS-31 pretreatment and acute treatment demonstrated significant reduction in infarct size and preservation of organ function markers.
Zhao K et al. 2007 ↗Mitochondrial Aging
SS-31 administration in aged rodents was associated with improved skeletal muscle mitochondrial function, increased ATP production rates, and improved physical performance markers in published research.
Siegel MP et al. 2013 ↗Renal Protection
SPYRAL trial and preclinical renal data demonstrated SS-31's nephroprotective potential, with reduced acute kidney injury markers and improved renal function in ischemia models.
Birk AV et al. 2013 ↗Compound Information
Technical specifications